A randomised trial to compare two solutions â?? HTK[Histidine-Tryptophan-Ketoglutarate] solution and IGL-1[Institut of georges Lopez-1] solution in perfusing Liver Donor Grafts during cold preservation and bench work[preparing grafts before transplant] during Living Donor Liver Transplantation

Randomized trial comparing Histidine-Tryptophan-Ketoglutarate solution and IGL-1(Institut of Georges Lopez-1) as perfusants for live donor liver transplantation grafts - RAHI

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/03/023883

Enrollment

148

Registered

2020-03-11

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K746- Other and unspecified cirrhosis ofliver

Interventions

Intervention1: Institut of Georges Lopez[IGL-1] solution: Internationally accepted standard solution which has recently gained prominence and is increasingly being used solution for perfusion of livin

Eligibility

Inclusion criteria

Inclusion criteria: All adult patients undergoing Living Donor Liver Transplantation in Amrita Institute of Medical Sciences

Exclusion criteria

Exclusion criteria: APOLT ABO incompatible transplants Pediatric transplants

Design outcomes

Primary

Measure	Time frame
Early allograft dysfunction [Day 7 Bilirubin greater than 10, Day 7 INR greater than 1.6, Peak SGOT/PT greater than 2000]Timepoint: First week after surgery	—

Secondary

Measure	Time frame
90 day mortalityTimepoint: 6 months after surgery;Acute Cellular RejectionTimepoint: 6 months after surgery;Bile leak, Biliary strictureTimepoint: 6 months after surgery;Hepatic artery thrombosisTimepoint: 6 months after surgery	—

Countries

India

Contacts

Public ContactSAI TARUN

AMRITA INSTITUTE OF MEDICAL SCIENCES

saitarun@yahoo.com7893285239

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026